Zydus Lifesciences signed a definitive agreement through its subsidiary, Zydus Worldwide DMCC, to acquire Assertio Holdings Inc. in an all-cash transaction valued at approximately $166.4 million. Assertio, a Nasdaq-listed pharmaceutical company, specializes in oncology supportive-care and other specialty therapies. Through the acquisition, Zydus aims to strengthen its foothold in the US specialty oncology market and accelerate its global specialty pharma strategy.
Strategic Push into Specialty and Oncology Therapies
Sharvil Patel, Managing Director, Zydus Lifesciences said the transaction aligns with the company’s long-term vision of building differentiated and sustainable specialty businesses globally. “This transaction represents a strategic step in strengthening our specialty and oncology footprint in the US. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy,” Patel added.
Focus on Long-Term Growth in the US Market
With the acquisition of Assertio, Zydus plans to leverage the company’s established oncology relationships, specialty sales network, and commercial capabilities to expand its specialty drug portfolio in the United States. As reported by msn.com, the deal further highlights Zydus’ growing emphasis on specialty therapies, oncology, and value-driven acquisitions aimed at strengthening its presence in regulated global markets.
